Detalhe da pesquisa
1.
Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF Trial.
J Card Fail
; 29(9): 1324-1328, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230315
2.
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Diabetes Obes Metab
; 25(1): 46-55, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111434
3.
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
Circulation
; 143(17): 1673-1686, 2021 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33550815
4.
Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study.
Am Heart J
; 243: 232-239, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34666013
5.
Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study.
Diabetes Obes Metab
; 24(9): 1734-1740, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35546275
6.
Unifying the analysis of continuous and categorical measures of weight loss and incorporating group effect: a secondary re-analysis of a large cluster randomized clinical trial using Bayesian approach.
BMC Med Res Methodol
; 22(1): 28, 2022 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081912
7.
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.
BMC Endocr Disord
; 22(1): 111, 2022 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35473607
8.
Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
Diabetes Obes Metab
; 23(8): 1823-1833, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852202
9.
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study.
Diabetes Obes Metab
; 23(10): 2336-2343, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34212481
10.
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
Diabetes Obes Metab
; 23(8): 1956-1960, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852196
11.
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Diabetes Obes Metab
; 23(6): 1426-1430, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33606921
12.
Meta-analysis of dose selection for budesonide in the treatment of Chinese patients with AECOPD.
J Pak Med Assoc
; 71(8): 2018-2026, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34418023
13.
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Circulation
; 140(18): 1463-1476, 2019 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31524498
14.
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Diabetes Obes Metab
; 22(1): 66-78, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468637
15.
Associations of fear of hypoglycemia with second-line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study.
Int J Clin Pract
; 74(6): e13485, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32003099
16.
Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
Diabetes Obes Metab
; 21(8): 1985-1989, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968543
17.
Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry.
Diabetes Obes Metab
; 21(2): 393-396, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30136353
18.
Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison.
Diabetes Obes Metab
; 21(2): 261-266, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30136348
19.
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Diabetes Obes Metab
; 21(11): 2474-2485, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31297947
20.
Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
Am Heart J
; 203: 25-29, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30015065